Skip to main content
Premium Trial:

Request an Annual Quote

ATCC Licenses CRISPR/Cas9 Tech From Broad Institute

NEW YORK (GenomeWeb) – ATCC, a biological materials resource and standards organization, has licensed CRISPR/Cas9 genome engineering technology from the Broad Institute.

ATCC said it plans to use the technology to develop new products and services for basic and translational research, similar to an EML4-ALK Fusion isogenic cell line the firm has already developed using the technology, which can be used for drug discovery and molecular diagnostics of non-small cell lung cancer. The newly developed cell line is more sensitive to the ALK inhibitor crizotinib when compared to its parent cell line and serves as a vital model to study cell signaling pathways in cancer as well as in drug screening, the firm said.

"The rapid growth of CRISPR/Cas9 applications provides a perfect environment for ATCC to leverage our comprehensive portfolio of cells, microorganisms, and services to meet the unmet demands of global researchers to support their scientific discoveries," Mindy Goldsborough, VP and General Manger of ATCC Cell Systems, said in a statement. The licensing agreement "allows ATCC scientists to unlock the full potential of our unique portfolio for creating standards for basic and translational research."

The agreement is the latest deal the Broad has cut to license CRISPR/Cas9 technology. Last month, it signed a similar agreement with Transposagen, and has licensed CRISPR to several other companies including GE Healthcare and Sigma-Aldrich.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.